GlassScriptPhysician profile
Terri S Steele
NPI 1730108192
$7,163.57
in general payments reported to CMS, 2019-2025
25 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $434 · 2021: $409 · 2022: $701 · 2023: $1,471 · 2024: $1,605 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,247 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,246.72 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,216.35 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $776.37 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $764.79 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Teva Pharmaceuticals USA, INC. | $653.12 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $568.91 | 2023-2025 | Caplyta |
| Alkermes, INC. | $554.91 | 2019-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $478.47 | 2021-2025 | Trintellix |
| Lundbeck LLC | $418.08 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $340.44 | 2019-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $277.49 | 2019-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $229.91 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $224.81 | 2023-2025 | Auvelity |
| Allergan, INC. | $174.26 | 2019-2020 | |
| Indivior INC. | $107.69 | 2019-2021 | |
| Bausch Health US, LLC | $88.25 | 2022-2024 | Aplenzin, Wellbutrin |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $46.69 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.40 | 2025 | Rexulti |
| Almatica Pharma LLC | $43.07 | 2022-2024 | Loreev Xr |
| Tris Pharma INC | $41.58 | 2024 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $25.30 | 2019 | |
| Neuronetics, INC. | $21.38 | 2025 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $19.24 | 2019 | |
| Orexo US, INC. | $16.49 | 2022 | |
| Shire North American Group INC | $16.08 | 2019 | |
| Sage Therapeutics, LLC | $14.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.